| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Desai Arjun Jj, Director
Granted 3,549 stock option |
| 13 Nov 2026 |
Form 4: Jacobovitz Shalom, Director
Granted 4,591 stock option |
| 13 Nov 2026 |
Form 4: Mosca Alison, Director
Granted 4,707 stock option |
| 13 Nov 2026 |
Form 4: Kiernan Matthew, Director
Granted 3,086 stock option |
| 13 Nov 2026 |
Form 4: Matlin David J, Director
Granted 6,019 stock option |
| 13 Nov 2026 |
Form 4: Gay Jonathon, Director
Granted 3,665 stock option |
| 13 Nov 2026 |
Form 4: McLaughlin Vallerie, Director
Granted 3,395 stock option |
| 13 Nov 2026 |
Form 4: Wilcox Reed N, Director
Granted 3,395 stock option |
| 04 Nov 2026 | FORM 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS) |
| 21 Oct 2026 |
Form 4: Etherington Robert Dee, Director
Granted 55,000 stock option |
| 21 Oct 2026 |
Form 4: Mortenson Mark, Chief Science Officer
Granted 30,000 stock option |
| 21 Oct 2026 |
Form 4: Brown Morgan R, Chief Financial Officer
Granted 20,000 stock option |
| 20 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS) |
| 19 Oct 2026 |
8-K: Other Events
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes |
| 13 Oct 2026 | SCHEDULE 13G/A |
| 18 Sep 2026 |
Form 4: Matlin David J, Director
Received 434,451 shares as a grant or award ($1.42M) |
| 18 Sep 2026 |
Form 4: Etherington Robert Dee, Director
Received 15,244 shares as a grant or award ($50K) |
| 18 Sep 2026 |
Form 4: Mosca Alison, Director
Received 198,171 shares as a grant or award ($650K) |
| 16 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its success... |
Loading...